Tiziana Life Sciences has updated investors on its lead programs in development along with the release of its financial results for the year ended December 31, 2022.
The biotechnology company's interim CEO Gabriele Cerrone said that, after it announced in late 2022 its near-term focus on advancing intranasal foralumab to address central nervous system-mediated inflammatory diseases, Tiziana has started this year with a stream of continuous, positive program-related developments.
The team from Yorkville Asset Management Inc attended the opening ceremony for a new long-term care home in Ontario, owned by Southbridge Health Care.
The Southbridge Cornwall Long-Term Care Home hosts 160 beds for residents over eight acres in the town of Cornwall, Ontario.
Gander Gold said it has identified three large zones of interest at its Cape Ray II gold project in southwest Newfoundland.
The three zones - Doughball Jog, Sou'wester, and Cabot - were identified using nearly 4,500 soil samples, geophysics surveys, and structural interpretation, the company said.
Century Lithium Corp. (TSX-V:LCE, OTCQX:CYDVF) has earned an ‘Outperform’ rating from Noble analysts who noted the competitive advantages of the company’s 100%-owned Clayton Valley lithium project located near Silver Peak in Nevada.
“Clayton Valley offers several competitive advantages, including a large land package in a mining-friendly state, an existing lithium carbonate equivalent resource base, well-developed infrastructure, direct lithium extraction technology, a fully operational pilot plant, and secured water rights,” the analysts wrote in a note to clients.
ACME Lithium Inc. (CSE:ACME, OTCQB:ACLHF) has completed the 2023 winter drill program at its Shatford Lake and Birse Lake lithium projects in Manitoba.
The program included eight holes totaling 3,280 meters of diamond drilling. Pegmatites were encountered in 6 of 8 holes, and 235 samples have been cut for assay, the company said.
Chesapeake Financial Shares Inc. (OTCQX:CPKF), the parent company of Chesapeake Bank and Chesapeake Wealth Management, told investors that its deposit base has held firm in the wake of the Silicon Valley Bank (SVB) failure.
Announcing first-quarter results, Chesapeake Bank CEO Jeffrey Szyperski commented: “The circumstances related to that failure were idiosyncratic to them and not correlated to what we do as an institution.”
Toubani Resources Inc. (TSX-V:TRE, ASX:TRE) has reported positive results from its drilling programme at the Kobada gold project in southern Mali, highlighting 6 metres (m) at 0.85 grams per tonne (g/t) gold, including 2m at 1.70 g/t, 1m at 3.58 g/t, and another 1m at 3.35 g/t.
Phil Russo, CEO of Toubani Resources, called the outcome “an excellent result”, confirming “the potential for Toubani to delineate new discoveries within the Kobada project”.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) has highlighted that the analysis on the so far successful Hickory exploration well, onshore Alaska, has met or exceeded its pre-drill aims and was completed on budget.
The Hickory-1 exploration well was spudded on 9 March and reached a total depth of 10,650 feet, with initial findings confirming the presence of multiple hydrocarbon-bearing pay zones across all of the explorer’s pre-drill targets.
Medical imaging technology specialist Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) said it has received its first order for a XENOVIEW gas blend cylinder.
Cincinnati Children's Hospital Medical Center placed the order for the xenon Xe 129 hyperpolarised blend that has the capacity to supply over 100 patient scans.
Rooster Talk 72 with Andrew Radonjic is all about Venture Minerals Limited (ASX:VMS, OTC:VTMLF) building a rare earth project portfolio.
It is no surprise that Venture Minerals is now adding rare earths to its portfolio. The creation of a decarbonisation mineral exploration portfolio makes complete sense.
Ioneer Ltd (ASX:INR, OTC:GSCCF)’s Rhyolite Ridge Lithium-Boron Project in Nevada is proving its pivotal role in the future electrification of transportation in the US, with a 145% increase in tonnage for the South Basin mineral resource estimate (MRE) to 360 million tonnes.
The JORC-compliant MRE contains 3.4 million tonnes of lithium carbonate equivalent (LCE), an increase of 168% and 14.1 million tonnes of boric acid equivalent (BAE), up 18%.
Imugene Ltd (ASX:IMU, OTC:IUGNF) has secured a research and development (R&D) tax refund from the Australian Government’s R&D tax incentive scheme, netting $A12.6 million in funding that would have otherwise been lost to taxes.
The R&D tax incentive scheme offers companies engaging in eligible activities with a refundable tax offset of up to 43.5%.
NV Gold Corporation said it has approved the issuance of 1,225,000 stock options to officers, directors and consultants of the company to purchase up to 1,225,000 common shares under its Stock Option Plan. Each option vested immediately and is exercisable for a period of five years at an exercise price of $0.07 per share, subject to the approval of the TSX Venture Exchange.
Japan Gold Corp has launched a non-brokered private placement of up to 50,000,000 common shares at a price of C$0.20 each for gross proceeds of up to C$10 million. The company said the proceeds will be used for drill programs, drill targeting, advancing the prospect pipeline from its large portfolio of exploration projects, and for general working capital purposes.
Sidus Space Inc said it has closed its underwritten public offering of 34,090,904 shares of its Class A common stock, or pre-funded warrants, and 34,090,904 warrants, which included the partial exercise of the underwriters’ over-allotment option. Each share of Class A common stock and accompanying warrant was sold to the public at a combined price of $0.33. Each warrant allows the purchase of one share of Class A common stock at an exercise price of $0.33 per share. The gross proceeds to the Company from this offering were approximately $11.2 million before deducting underwriting discounts, commissions and other offering expenses. Sidus Space intends to use the net proceeds of the offering for sales and marketing, operational costs, product development, manufacturing expansion and the remaining proceeds for working capital and other general corporate purposes.
Immunic Inc has announced its participation at the following investor and scientific conferences in May:
The Aegis Virtual Conference, being held May 2-4. Dr Daniel Vitt the company’s chief executive officer and president will present a company overview at this virtual conference on Thursday, May 4, 2023, at 11.00am ET.
The ISIRV-AVG Conference, Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19, being held May 3-5. Dr Hella Kohlhof, the company’s chief scientific officer will present preclinical data on the antiviral properties of dihydroorotate dehydrogenase (DHODH) inhibitors in an oral presentation at this conference in Seattle, Washington. The presentation, being delivered on Wednesday, May 3, 2023, at 3.00pm-3.15 pm PT (6.00pm-6.15 pm ET).
The 8th European Congress of Virology 2023 being held May 4-7. Dr Alexandra Herrmann, program manager Virology at Immunic, will present preclinical broad-spectrum antiviral activity data for newly developed DHODH inhibitors in a poster presentation at this conference in Gdańsk, Poland on Friday, May 5, 2023, at 7.00pm CET (1.00pm ET).
Digestive Disease Week 2023 being held May 6-9. Dr Franziska Buriánek, senior medical director at Immunic, will present phase 1 clinical data of IMU-856 in healthy human subjects in a virtual e-poster at this conference in Chicago, Illinois on Saturday, May 6, 2023, at 9.30am-4.00pm CT (10.30am-5.00pm ET).
The 23rd Bioequity Europe being held May 14-16 and 22-23. Dr Vitt will present a company overview on Monday, May 15, 2023, at 11.44am IST (6.44am ET) as part of the ‘Autoimmune, Inflammation and Thrombosis’ track at this conference in Dublin, Ireland.
The XXII National Congress of Neurology being held May 18-21. Dr Sonya Ivanova Hristova-Chakmakova, assistant Professor, Multiprofile Hospital for Active Treatment in Neurology and Psychiatry St. Naum, Sofia, Bulgaria, will present a poster presentation on the results of Immunic's phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis at this conference in Golden Sands, Bulgaria, on Sunday, May 21, 2023, at 9.30am-12.30pm EET (2.30am-5.30am ET.)
All the presentations and posters will be accessible on the ‘Events and Presentations’ section of Immunic's website at: https://ir.imux.com/events-and-presentations.
VolitionRx Limited said it is hosting a Capital Markets Day in a hybrid format (in-person and live-webcast) on Thursday, May 11, 2023, at 2.00pm Eastern Time, with the in-person venue being the Hamilton Suite, New York Stock Exchange, 11 Wall Street, New York. Volition's executive team will be joined by Key Opinion Leaders: Dr Andy Retter (Intensive Care Consultant) and Veterinary Oncologists, Professor Heather Wilson-Robles and Dr Sue Ettinger, aka Dr Sue Cancer Vet. A question-and-answer session with management will follow the prepared remarks and formal presentation. To attend the event in-person please contact investorrelations@volition.com, and to access the virtual event, register by using the following link: https://vimeo.com/webinars/events/d5a716f2-b112-4c56-a2ec-b2d16c7c21fb.
MySize Inc CEO Ronen Luzon will present at the Ladenburg Thalmann Tech Expo on Thursday, April 27, 2023 at 1pm ET on Track 2: Park Hub West, at Convene 101 Park Avenue, New York City. A Live webcast available for viewing at 1:00 PM ET here: https://wsw.com/webcast/ladenburg9/register.aspx?conf=ladenburg9&page=mysz&url=https://wsw.com/webcast/ladenburg9/mysz/2487639.
BioHarvest Sciences Inc will host a shareholder presentation on May 4 at 11am PST/2 pm EST. CEO Ilan Sobel will be joined by Chief Medical Officer Brian Cornblatt. "I am especially excited to have Dr. Brian Cornblatt join us for this shareholder update," stated CEO Ilan Sobel, adding, "Our clinical studies initiative is just one of the major building blocks of the company, but it is one that could have a profound impact on both our product roadmap, and our ability to improve people's lives. I look forward to a very energetic question and answer session with Brian." Link to register: https://us02web.zoom.us/webinar/register/WN_Mpgl8PuFSviafsnlk7P1og. As well, BioHarvest said that it will be adding quarterly financial update presentations to align communication of quarterly sales results and future guidance with its official and externally reviewed quarterly financial filing dates, as per the Canadian Securities Exchange. The firm said that will help the company to communicate and discuss quarterly results that include revenue (not sales orders) and other key financial performance metrics. BioHarvest will host the first financial update presentation on May 31st following the announcement of Q1/2023 results.